MERK's MEVACOR (LOVASTATIN) WILL BE TARGETED AT HYPERCHOLESTEROLEMICS AT HIGH RISK; ADVISORY PANEL RECOMMENDS APPROVAL, FREQUENT LIVER MONITORING

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".